Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up - Still a Buy?

Key Points

• Hypermarcas shares gapped up from $3.98 to $4.25 on Friday, with a trading volume of 2,312 shares.
• Scotiabank has upgraded Hypermarcas to a "strong-buy" rating, contributing to an overall average rating of "Strong Buy" for the stock.
• The company reported $0.12 earnings per share in its latest quarterly results, with a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.98, but opened at $4.25. Hypermarcas shares last traded at $4.25, with a volume of 2,312 shares trading hands.

Wall Street Analyst Weigh In

Separately, Scotiabank upgraded Hypermarcas to a "strong-buy" rating in a research note on Thursday, July 17th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the company currently has an average rating of "Strong Buy".

Hypermarcas Stock Performance

The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. The stock's fifty day moving average price is $4.35 and its 200-day moving average price is $4.25. The company has a market capitalization of $2.65 billion, a P/E ratio of 19.91 and a beta of 0.83.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.